Dermatology

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.

In this case–control study, investigators identified relevant comorbidities among individuals with bullous pemphigoid before and after their diagnoses.

These data resulted from an investigation of the effect of varying image qualities on the diagnostic abilities of a convolutional neural network (CNN) model and clinicians.

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an assessment tool.

Investigators looked at the effects of the exposome among patients with atopic dermatitis in order to better understand the influence of such elements as obesity and microorganisms.

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa.

In part 4 of our series, expert dermatologists discuss the safety profile of bimekizumab in HS relative to other disease states and trials.

In this video series segment, expert dermatologsts prove ide insight into the strengths and limitations of IL-17 A/F inhibition in HS.

Expert dermatologists discuss the role of IL-17 A/F inhibition in the management of hidradenitis suppurativa.

In this 5-part, expert-led series, a pair of dermatologists break down how the FDA approval of bimekizumab impacts the treatment landscape of HS.

The phase 3 OLYMPIA 1 study highlights the benefits among those with prurigo nodularis of targeting interleukin-31 signaling using nemolizumab.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.

The November Month in Review features a set of dermatology news coverage highlights, including FDA news and developments in psoriasis.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.

The investigators concluded that chronic psychological stress substantially impacts skin homeostasis and, consequently, skin aging.

UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.

These data were announced by Protagonist Therapeutics, resulting from the 2 pivotal ICONIC-LEAD and ICONIC-TOTAL studies on the oral peptide icotrokinra.